Benjamin Edwards Inc Intellia Therapeutics, Inc. Transaction History

Benjamin Edwards Inc

$6.78 Billion
Q4 2024

A detailed history of Benjamin Edwards Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Benjamin Edwards Inc holds 64,065 shares of NTLA stock, worth $595,804. This represents 0.01% of its overall portfolio holdings.

Number of Shares

64,065

Previous 57,669 11.09%

Holding current value

$595,804

Previous $1.19 Million 37.05%

% of portfolio

0.01%

Previous 0.02%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$11.41 - $21.09 $72,978 - $134,891	6,396 Added 11.09%	64,065 $746,000
Q3 2024 Nov 14, 2024	BUY	$19.72 - $27.36 $1.13 Million - $1.57 Million	57,253 Added 13762.74%	57,669 $1.19 Million
Q2 2024 Aug 12, 2024	SELL	$20.02 - $27.22 $2,922 - $3,974	-146 Reduced 25.98%	416 $9,000
Q1 2024 Apr 29, 2024	BUY	$23.82 - $32.8 $833 - $1,148	35 Added 6.64%	562 $15,000
Q4 2023 Feb 06, 2024	SELL	$23.16 - $32.34 $7,341 - $10,251	-317 Reduced 37.56%	527 $16,000
Q3 2023 Nov 13, 2023	BUY	$31.62 - $45.78 $2,466 - $3,570	78 Added 10.18%	844 $27,000
Q2 2023 Aug 15, 2023	BUY	$34.58 - $46.03 $622 - $828	18 Added 2.41%	766 $31,000
Q1 2023 Apr 27, 2023	BUY	$33.3 - $44.82 $1,265 - $1,703	38 Added 5.35%	748 $28,000
Q4 2022 Feb 07, 2023	BUY	$33.21 - $62.69 $4,682 - $8,839	141 Added 24.78%	710 $25,000
Q3 2022 Oct 28, 2022	SELL	$53.92 - $71.7 $2,372 - $3,154	-44 Reduced 7.18%	569 $32,000
Q2 2022 Aug 12, 2022	BUY	$38.49 - $76.21 $230 - $457	6 Added 0.99%	613 $32,000
Q1 2022 May 04, 2022	SELL	$58.27 - $118.99 $4,719 - $9,638	-81 Reduced 11.77%	607 $44,000
Q4 2021 Feb 07, 2022	BUY	$100.76 - $138.36 $3,627 - $4,980	36 Added 5.52%	688 $81,000
Q3 2021 Nov 02, 2021	SELL	$132.37 - $176.78 $26,209 - $35,002	-198 Reduced 23.29%	652 $87,000
Q2 2021 Aug 11, 2021	SELL	$60.88 - $161.91 $26,969 - $71,726	-443 Reduced 34.26%	850 $138,000
Q1 2021 May 14, 2021	SELL	$46.59 - $83.68 $372 - $669	-8 Reduced 0.61%	1,293 $104,000
Q4 2020 Feb 16, 2021	SELL	$18.83 - $63.53 $11,166 - $37,673	-593 Reduced 31.31%	1,301 $71,000
Q3 2020 Nov 16, 2020	BUY	$17.47 - $24.93 $1,345 - $1,919	77 Added 4.24%	1,894 $38,000
Q1 2020 May 07, 2020	SELL	$9.44 - $15.58 $575 - $950	-61 Reduced 3.25%	1,817 $22,000
Q4 2019 Feb 06, 2020	BUY	$10.43 - $17.67 $2,325 - $3,940	223 Added 13.47%	1,878 $28,000
Q3 2019 Nov 05, 2019	SELL	$13.07 - $18.51 $470 - $666	-36 Reduced 2.13%	1,655 $22,000
Q2 2019 Aug 08, 2019	BUY	$13.88 - $18.41 $8,883 - $11,782	640 Added 60.89%	1,691 $28,000
Q1 2019 May 15, 2019	BUY	$12.79 - $17.62 $13,442 - $18,518	1,051 New	1,051 $18,000

Others Institutions Holding NTLA

# of Institutions

336

Shares Held

96.1M

Call Options Held

1.06M

Put Options Held

863K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $707M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Benjamin Edwards Inc, based on Form 13F filings with the SEC.

News

Stay updated on Benjamin Edwards Inc with notifications on news.

Account

Benjamin Edwards Inc Intellia Therapeutics, Inc. Transaction History